Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cells injected into heart arteries may help repair damage after a heart attack

NCT ID NCT05724576

Disease control Sponsor: Taiwan Bio Therapeutics Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a single dose of donor stem cells (OmniMSC-AMI) given directly into the heart arteries is safe for people who have just had a major heart attack. The study enrolls adults aged 20–80 with a specific type of heart attack (anterior STEMI) who are treated within 6 hours. Researchers will monitor side effects and measure heart function over time to see if the stem cells might help the heart pump better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OmniMSC-AMI (donor bone marrow stem cells)
What this could lead to
If safe and effective, this approach could help repair heart muscle after a heart attack and improve pumping function.
What could go wrong
This is a very early, small safety trial with only 10 people. It is not designed to prove the treatment works, and stem cell therapies carry risks like inflammation or arrhythmia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

1 person

The number who actually took part.

Started

Jun 2023

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patents, with age ≤20 or ≤80 years old. * Fit to the definition of ST-elevation myocardial infarction (anterior myocardial infarction): 1. Chest pain onset. 2. 12-lead EKG:V1-V6 ≥ consecutive lead ST-segment elevation ≥1 mm. 3. TnT-I elevation. * Into emergency ≤ 6h upon AMI presentation. * Patients are willing to receive the treatment and sign the informed consent. Exclusion Criteria: * Age \< 20 or \>80 years old. * History of 1. Malignancy. 2. Sepsis (abnormal WBC count elevation). 3. Hematologic disorder. 4. AIDS. 5. Advanced liver cirrhosis. 6. CKD stage 5 with Ccr \<15 ml/min. * AMI occurrence \> 6 hours * Non-first AMI. * Pregnancy or breastfeeding. * Prison. * Cancer treatment within 2 years. * Expected lifespan \< 6 months. * Non-suitable candidate evaluated by PI. * Participating in other clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Safety issues are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Safety issues

Contacts and locations

Locations

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.